Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27214747 | 0.84 | ALDH1A1 (0.56) | GPR119KMT2AUSP30PTPN2PTPN1 | |
| SCHEMBL24833605 | 0.83 | MGLL (0.56) | GPR119KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL21088061 | 0.81 | KMT2A (0.54) | GPR119KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL20057626 | 0.78 | GPR119 (0.83) | GPR119 | |
| SCHEMBL12426680 | 0.76 | HDAC4 (0.61) | GPR119KMT2AUSP30MEN1 | |
| SCHEMBL27178814 | 0.76 | PDK2 (0.54) | GPR119KMT2AUSP30MEN1PTPN2 | |
| SCHEMBL14113582 | 0.75 | GPR119 (0.55) | GPR119KMT2A | |
| SCHEMBL1087013 | 0.75 | HPGD (0.60) | GPR119KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL270733 | 0.75 | NAMPT (0.60) | GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL2849980 | 0.75 | KMT2A (0.54) | GPR119KMT2AMEN1PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594319-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240150351-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024073559-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150351-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | GPR119 855/4885KMT2A 3870/4885USP30 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.